Search Results - "Margelí, M."

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study by Oliveira, M., Falato, C., Cejalvo, J.M., Vila, M. Margelí, Tolosa, P., Salvador-Bofill, F.J., Cruz, J., Arumi, M., Luna, A.M., Guerra, J.A., Vidal, M., Martínez-Sáez, O., Paré, L., González-Farré, B., Sanfeliu, E., Ciruelos, E., Espinosa-Bravo, M., Pernas, S., Izarzugaza, Y., Esker, S., Fan, P.-D., Parul, P., Santhanagopal, A., Sellami, D., Villacampa, G., Ferrero-Cafiero, J.M., Pascual, T., Prat, A.

“…Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody–drug conjugate composed of a fully human anti-HER3…”
Get full text

SEOM clinical guidelines in early stage breast cancer (2018) by Ayala de la Peña, F., Andrés, R., Garcia-Sáenz, J. A., Manso, L., Margelí, M., Dalmau, E., Pernas, S., Prat, A., Servitja, S., Ciruelos, E.

“…Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around…”
Get full text

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) by Albanell, J., Martínez, M.T., Ramos, M., O'Connor, M., de la Cruz-Merino, L., Santaballa, A., Martínez-Jañez, N., Moreno, F., Fernández, I., Alarcón, J., Virizuela, J.A., de la Haba-Rodríguez, J., Sánchez-Rovira, P., González-Cortijo, L., Margelí, M., Sánchez-Muñoz, A., Antón, A., Casas, M., Bezares, S., Rojo, F.

“…The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2…”
Get full text

Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report by L, Angelats, A, Estival, A, Martinez-Cardús, E, Musulen, M, Margelí

“…We report a case of a 68-year-old man who developed an advanced Triple-Negative Breast Cancer (TNBC) presented as a Carcinoma of Unknown Primary (CUP) at…”
Get full text

Information and communication technology systems to improve quality of life and safety of Alzheimer's disease patients: a multicenter international survey by Pilotto, Alberto, D'Onofrio, Grazia, Benelli, Edoardo, Zanesco, Antonio, Cabello, Ana, Margelí, M Carmen, Wanche-Politis, Sophia, Seferis, Kostas, Sancarlo, Daniele, Kilias, Dimitrios

“…Within the frame of the European Commission funded Smart Home for Elderly People (HOPE) Project, relatives/caregivers of 223 Alzheimer's Disease (AD) patients…”
Get more information

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens by Blancas, I., Aguirre, E., Morales, S., Gonzálvez, M. L., Servitja, S., Díaz, N., del Barco, S., Barnadas, A., Margelí, M., García Carbonero, I., Llombart, A.

“…Purpose To evaluate the efficacy and safety of oral weekly vinorelbine 60 mg/m 2 for metastatic breast cancer (MBC) in patients previously treated with…”
Get full text

Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single‐arm trial by Buckland, G., Travier, N., Arribas, L., del Barco, S., Pernas, S., Zamora, E., Bellet, M., Cirauqui, B., Margelí, M., Muñoz, M., Tusquets, I., Arcusa, A., Javierre, C., Moreno, F., Valverde, Y., Jansen, E., Chajès, V., Castro, C., Agudo, A.

“…Background The influence of nutrition on breast cancer prognosis is still inconclusive and therefore dietary interventions incorporating dietary biomarkers are…”
Get full text

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial by Barnadas, A, Gil, M, González, S, Tusquets, I, Muñoz, M, Arcusa, A, Prieto, L, Margelí-Vila, M, Moreno, A

“…To assess the efficacy of exemestane as neoadjuvant treatment, 55 postmenopausal women (mean age: 76 years; range: 66–86) with oestrogen-positive…”
Get full text

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) by Aparicio, J., Maroto, P., García del Muro, X., Sánchez-Muñoz, A., Gumà, J., Margelí, M., Sáenz, A., Sagastibelza, N., Castellano, D., Arranz, J.A., Hervás, D., Bastús, R., Fernández-Aramburo, A., Sastre, J., Terrasa, J., López-Brea, M., Dorca, J., Almenar, D., Carles, J., Hernández, A., Germà, J.R.

“…We aimed to analyze prognostic factors for relapse in stage I seminoma managed by either active surveillance or adjuvant chemotherapy, and to describe the…”
Get full text

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain by Font, R, Espinas, J A, Gil-Gil, M, Barnadas, A, Ojeda, B, Tusquets, I, Segui, M A, Margelí, M, Arcusa, A, Prat, A, Garcia, M, Borras, J M

“…Aims: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in…”
Get full text

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL by Martin, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Turner, N., Ciruelos, E.M., Muñoz, M., Bermejo, B., Margeli, M., Anton, A., Kahan, Z., Csöszi, T., Casas, M.I., Murillo, L., Morales, S., Alba, E., Gal-Yam, E., Guerrero-Zotano, A., Calvo, L., de la Haba-Rodriguez, J., Ramos, M., Alvarez, I., Garcia-Palomo, A., Huang Bartlett, C., Koehler, M., Caballero, R., Corsaro, M., Huang, X., Garcia-Sáenz, J.A., Chacón, J.I., Swift, C., Thallinger, C., Gil-Gil, M.

“…Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative,…”
Get full text

Influence of the 2019-novel coronavirus pandemic on the management of breast cancer by Luna Tomás, M A, Margelí Vila, M, Ríos Gozálvez, C

Get full text

DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer by Cirauqui, B., Margelí, M., Quiroga, V., Quer, A., Karachaliou, N., Chaib, I., Ramírez, J. L., Muñoz, A., Pollán, C., Planas, I., Drozdowsky, A., Rosell, R.

“…Platinum-based chemoradiotherapy (CRT) is a preferred standard of care for locally advanced head and neck cancer (HNC). However, survival benefit is small,…”
Get full text

Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound‐guided transbronchial needle aspiration by Serra, P., Sanz‐Santos, J., Castellà, E., Cirauqui, B., Andreo, F., Llatjós, M., Avila, M., Margelí, M., Serrano, L., Centeno, C., Quiroga, V., Torky, M., Ruiz‐Manzano, J.

“…Background In breast cancer patients, the expression statuses of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor…”
Get full text

0145 First safety data from a randomised phase III trial comparing adjuvant epirubicin–cyclophosphamide → docetaxel (EC → T) vs ET → capecitabine (X) in N+ operable breast cancer (BC) by Martín, M, Lluch, A, Ruiz-Simón, A, Ribelles, N, Ruiz-Borrego, M, Rodríguez-Lescure, A, Muñoz, M, Ramos, M, González, S, Margelí, M

Get full text

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study by Barnadas, A., Muñoz, M., Margelí, M., Chacón, J. I., Cassinello, J., Antolin, S., Adrover, E., Ramos, M., Carrasco, E., Jimeno, M. A., Ojeda, B., González, X., González, S., Constenla, M., Florián, J., Miguel, A., Llombart, A., Lluch, A., Ruiz-Borrego, M., Colomer, R., Del Barco, S.

“…Background Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life…”
Get full text

339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer by Manso, L., Pernas, S., Margelí, M., Blanch, S., Adamo, B., Salvador Bofill, F.J., Moreno, D., González, X., Pascual, T., Ferrero-Cafiero, J.M., Perou, C.M., Prat, A., Oliveira, M.

Get full text

Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial by Oakman, C., Francis, P.A., Crown, J., Quinaux, E., Buyse, M., De Azambuja, E., Margeli Vila, M., Andersson, M., Nordenskjöld, B., Jakesz, R., Thürlimann, B., Gutiérrez, J., Harvey, V., Punzalan, L., Dell'Orto, P., Larsimont, D., Steinberg, I., Gelber, R.D., Piccart-Gebhart, M., Viale, G., Di Leo, A.

“…In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin…”
Get full text

SEOM clinical guidelines in early-stage breast cancer 2015 by Garcia-Saenz, J. A., Bermejo, B., Estevez, L. G., Palomo, A. G., Gonzalez-Farre, X., Margeli, M., Pernas, S., Servitja, S., Rodriguez, C. A., Ciruelos, E.

“…Breast cancer is a major public health problem. Despite remarkable advances in early diagnosis and treatment, one in three women may have metastases since…”
Get full text

1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore) by Notario Rincon, L., Hierro, C., Esteve, A., Fontanals, S., González, A., Loureiro, E., Sun, C., Margelí, M., Moran, T., Font, A., Manzano, J.L., Balaña, C., Quiroga, V., Quer, N., Ibañez, C., Martínez-Benavides, J., Brunet, J., Clopes, A., Mesia, R.

Get full text